ACESO Research Labs LLP, promoter of Astral Laboratories Limited, acquired 21,007 equity shares worth ₹15.67 lakh through on-market transactions on BSE between March 11-19, 2026. The purchase increased the promoter's shareholding from 1,959,284 shares (4.64%) to 1,980,291 shares (4.69%). The company disclosed this transaction to BSE on March 19, 2026, in compliance with SEBI insider trading regulations.

Astral Laboratories Promoter ACESO Research Labs Acquires Additional 21,007 Shares

Astral laboratories Limited has disclosed a share acquisition by its promoter entity ACESO Research Labs LLP, as per regulatory requirements under SEBI (Prohibition of Insider Trading) Regulations, 2015. The transaction represents a strategic increase in the promoter's stake in the pharmaceutical company.

Transaction Details

ACESO Research Labs LLP executed the share purchase through on-market transactions on the BSE platform. The acquisition involved 21,007 equity shares at a total value of ₹15.67 lakh, excluding taxes, brokerage, and other charges.

Parameter Details Shares Acquired 21,007 Transaction Value ₹15.67 lakh Transaction Period March 11-19, 2026 Exchange BSE Transaction Type On-market purchase

Shareholding Changes

The acquisition resulted in an increase in ACESO Research Labs LLP's shareholding in Astral Laboratories Limited. The promoter's stake grew from 4.64% to 4.69% following the transaction.

Shareholding Position Before Transaction After Transaction Number of Shares 1,959,284 1,980,291 Percentage Holding 4.64% 4.69% Change in Shares - +21,007

Regulatory Compliance

Astral Laboratories Limited submitted the disclosure to BSE Limited on March 19, 2026, through its Company Secretary and Compliance Officer, Mahendra Kumar. The disclosure was made under Form C as required by Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

About the Entities

ACESO Research Labs LLP, identified by LLPIN AAX-0730 and PAN ABVFA0086A, operates from Bangalore, Karnataka. The entity is represented by Designated Partner Ravikanti Shailaja (DIN: 07629653). Astral Laboratories Limited, formerly known as Macro International Limited, is incorporated under CIN L74120UP1993PLC015605 with its registered office in Noida, Uttar Pradesh, and corporate office in Hyderabad, Telangana.

Several companies have submitted their unaudited financial results for the third quarter of FY26, covering the period ended December 31, 2025, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Astal Laboratories Limited Performance

Astal Laboratories Limited reported strong operational performance for Q3 FY26. The company's financial results were approved by the Board of Directors at their meeting held on February 14, 2026.

Financial Metric Q3 FY26 (₹ Lakhs) Q2 FY26 (₹ Lakhs) Q3 FY25 (₹ Lakhs) Revenue from Operations 5,223.53 3,751.64 1,445.88 Other Income 3.65 3.27 5.59 Total Revenue 5,227.18 3,754.91 1,451.47 Profit Before Tax 313.10 346.99 301.79 Net Profit 235.73 258.26 248.86 EPS Basic 2.189 2.395 2.528 EPS Diluted 1.738 1.972 2.528

Coromandel Agro Products and Oils Limited Results

Coromandel Agro Products and Oils Limited, registered in Andhra Pradesh, reported its quarterly performance with total income from operations reaching ₹2,708.80 lakhs for Q3 FY26.

Performance Metric Q3 FY26 (₹ Lakhs) Q2 FY26 (₹ Lakhs) Q3 FY25 (₹ Lakhs) Total Income from Operations 2,708.80 1,030.36 5,521.85 Net Profit After Tax 17.13 105.01 350.21 Equity Share Capital 79.00 79.00 79.00 Basic & Diluted EPS 2.17 13.29 44.33

Objective Information Systems Limited Performance

Objective Information Systems Limited, operating in the IT/ITES segment, submitted its unaudited results showing total income from operations of ₹392.58 lakhs for the quarter.

Key Metrics Q3 FY26 (₹ Lakhs) Q2 FY26 (₹ Lakhs) Q3 FY25 (₹ Lakhs) Total Income from Operations 392.58 360.72 1,828.61 Net Profit Before Tax 55.96 -12.51 132.61 Net Profit After Tax 57.43 -18.05 84.04 Equity Share Capital 105.12 105.12 105.12 Basic & Diluted EPS 0.55 -0.17 0.80

Regulatory Compliance and Publication

All companies have published their financial results in leading newspapers including The Financial Express, The Business Standard, and The Jansatta as required under Regulation 47 of the SEBI regulations. The results have also been made available on respective company websites and BSE's official portal for investor access.

Business Operations Overview

Astal Laboratories operates in manufacturing and trading of active pharmaceutical ingredients, while Coromandel Agro Products focuses on agro-based products and oils. Objective Information Systems operates primarily in the IT services sector. All companies have prepared their financial results in accordance with Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.